Keratosis

AmLactin® Announces Partnership with U.S. Figure Skating Champion Amber Glenn

Retrieved on: 
Tuesday, January 16, 2024
Olympic Games, Wollman Rink, Partnership, Lactic acid, Upsher-Smith Laboratories, Skin, Keratosis, Prize, United States national team, Ice, Cosmetics

BRIDGEWATER, N.J., Jan. 16, 2024 /PRNewswire/ -- AmLactin, the #1 dermatologist recommended moisturizer brand with lactic acid, is announcing today a one-year partnership with Team USA Figure Skater Amber Glenn for the #IAmLactinReady campaign where she will discuss her personal skincare journey with Keratosis Pilaris through a series of social posts that will run throughout 2024. Amber will also showcase how AmLactin keeps her skin soft and smooth, during the harsh winter months and throughout all the seasonal changes that can affect skin. 

Key Points: 
  • "I am thrilled to embark on this incredible mission with AmLactin for the #IAmLactinReady Uncover Your True Skin campaign," said Team USA Figure Skater Amber Glenn.
  • I hope my story can empower others on their road to uncovering their own true skin confidence," added Glenn.
  • To meet Amber Glenn in person and learn more about her skincare journey, play the #IAmLactinReady Instant Win Game at www.amlactin.com/pages/game for a chance to win.
  • "We are excited about this unique opportunity to partner with Amber Glenn for the #IAmLactinReady campaign.

United States Actinic Keratosis Market and Competitive Landscape Report 2022: Treatments, Pipeline, Epidemiology, Marketed Products, Valuations and Forecasts, Drugs Sales and Market Shares 2019-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Health, General Health, Competitive landscape, Research, Keratosis, Epidemiology, Risk management, Pharmaceutical industry

The report US Actinic Keratosis Market and Competitive Landscape Highlights - 2022, provides comprehensive insights into Actinic Keratosis pipeline products, Actinic Keratosis epidemiology, Actinic Keratosis market valuations and forecast, Actinic Keratosis drugs sales and competitive landscape in the US.

Key Points: 
  • The report US Actinic Keratosis Market and Competitive Landscape Highlights - 2022, provides comprehensive insights into Actinic Keratosis pipeline products, Actinic Keratosis epidemiology, Actinic Keratosis market valuations and forecast, Actinic Keratosis drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Actinic Keratosis treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Actinic Keratosis pipeline: Find out the products in clinical trials for the treatment of Actinic Keratosis by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Actinic Keratosis drugs: Identify key products marketed and prescribed for Actinic Keratosis in the US, including trade name, molecule name, and company
    Actinic Keratosis market valuations: Find out the market size for Actinic Keratosis drugs in 2021 in the US.
  • Find out how the market advanced from 2019 and forecast to 2027
    Actinic Keratosis drugs market share: Find out the market shares for key Actinic Keratosis drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Actinic Keratosis products

Europe Actinic Keratosis Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 2, 2021
Pharmaceutical, Health, Oncology, Keratosis, Competitive landscape, Research, Epidemiology, Prevalence, Fine chemical, Pharmaceutical industry

The "Europe Actinic Keratosis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Actinic Keratosis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Actinic Keratosis Market and Competitive Landscape - 2021, provides comprehensive insights into Actinic Keratosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Actinic Keratosis treatment options, Actinic Keratosis late-stage clinical trials pipeline, Actinic Keratosis prevalence by countries, Actinic Keratosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Actinic Keratosis pipeline: Find out drugs in clinical trials for the treatment of Actinic Keratosis by development phase 3, phase 2, by pharmacological class and company
    Actinic Keratosis drugs: Identify key drugs marketed and prescribed for Actinic Keratosis in the US, including trade name, molecule name, and company
    Actinic Keratosis market valuations: Find out the market size for Actinic Keratosis drugs in 2020 by countries.

Global Actinic Keratosis Markets and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 10, 2021
Health, General Health

The "Global Actinic Keratosis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Actinic Keratosis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Actinic Keratosis Market and Competitive Landscape - 2021, provides comprehensive insights into Actinic Keratosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Actinic Keratosis treatment options, Actinic Keratosis late-stage clinical trials pipeline, Actinic Keratosis prevalence by countries, Actinic Keratosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Actinic Keratosis pipeline: Find out drugs in clinical trials for the treatment of Actinic Keratosis by development phase 3, phase 2, by pharmacological class and company
    Actinic Keratosis drugs: Identify key drugs marketed and prescribed for Actinic Keratosis in the US, including trade name, molecule name, and company
    Actinic Keratosis market valuations: Find out the market size for Actinic Keratosis drugs in 2020 by countries.

Global Actinic Keratosis Treatment Market 2021-2029 - Market Opportunities in the Lucrative Future for Light-based Treatments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Health, Oncology, Actinic keratosis, Dermatology, Keratosis, Actinism, AK, Physical sciences, Physical phenomena, Chemistry

The actinic keratosis (AK) treatment market is anticipated to grow at a CAGR of about 4.5% during the forecast period 2021-2029.

Key Points: 
  • The actinic keratosis (AK) treatment market is anticipated to grow at a CAGR of about 4.5% during the forecast period 2021-2029.
  • Threat related with untreated actinic keratosis is 20% higher than treated actinic keratosis.
  • Whereas, lack of awareness related to actinic keratosis, is a major setback in the treatment of AK.
  • The reasons for growth of AK treatment market in North American and European actinic keratosis market are advanced healthcare infrastructure, awareness among people related to the disease and its treatment, high income, favourable regulatory framework and reimbursements.

Almirall delivers robust H1 performance and increases full-year guidance

Retrieved on: 
Monday, July 26, 2021
Almirall, Actinic keratosis, Keratosis, Earnings before interest, taxes, depreciation and amortization, Actinism, Physical sciences, Natural sciences, Economy

BARCELONA, Spain, July 26, 2021 /PRNewswire/ -- Almirall, S.A. (BME: ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2021 financial results.

Key Points: 
  • I am very confident about the direction of the company and its performance.
  • Almirall continues developing an extensive EU rollout campaign supported by long-term data that confirms Ilumetri's efficacy and safety profile.
  • Full year Core Guidance updated.Core Net Sales* mid-single-digit growth, Core EBITDA** between 195 - 215 MM (previously between 190 - 210 MM).
  • [ii] Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective.

Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis

Retrieved on: 
Monday, July 19, 2021
Chemistry, Chemical compounds, Physical sciences, Amides, Ethers, Morpholines, Pyridines, Tirbanibulin, Actinic keratosis, Almirall, Keratosis, AK

BARCELONA, Spain, July 19, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the European Commission (EC) has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp in adults.

Key Points: 
  • BARCELONA, Spain, July 19, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the European Commission (EC) has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp in adults.
  • "The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek for new treatments that could offer them a better tolerability and short treatment duration.
  • In addition, Almirall has submitted Klisyri for a marketing authorisation in Switzerland in Q4 2020 and the dossier is currently under review by Swissmedic.
  • [4]Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective.

Almirall receives European Commission approval of Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis

Retrieved on: 
Monday, July 19, 2021
Pharmaceuticals policy, Health care, Chemistry, Health, Actinic keratosis, Dermatology, Swissmedic, Tirbanibulin, Keratosis, Almirall, Marketing authorisation, Actinism

"The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek new treatments that could offer them better tolerability and short treatment duration.

Key Points: 
  • "The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek new treatments that could offer them better tolerability and short treatment duration.
  • In addition, Almirall submitted Klisyri for a marketing authorisation in Switzerland in December 2020 and the dossier is currently under review by Swissmedic.
  • The company has already submitted in Great Britain via the European Commission Decision Reliance Procedure.
  • Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective.

How to Treat Keratosis Pilaris at Home; American Academy of Dermatology

Retrieved on: 
Thursday, June 24, 2021
Genodermatoses, Keratosis pilaris, Keratosis, Medical specialties, Medicine, Clinical medicine, Chicken skin, Keratosis pilaris atrophicans

Keratosis pilaris causes tiny, rough feeling bumps to appear on the skin, most often on the upper arms and thighs.

Key Points: 
  • Keratosis pilaris causes tiny, rough feeling bumps to appear on the skin, most often on the upper arms and thighs.
  • While treatment isnt necessary for keratosis pilaris, if the itch, dryness or appearance is bothersome, there are things you can do at home to help.
  • Spending too much time in the water can dry your skin and cause keratosis pilaris to flare.
  • These tips are demonstrated in How to Treat Keratosis Pilaris at Home , a video posted to the AAD website and YouTube channel .

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Retrieved on: 
Wednesday, June 9, 2021
Science, Other Science, Biotechnology, Practice Management, General Health, Health, Medical devices, Genetics, Anatomy, Branches of biology, Organ systems, Wart, Sebaceous gland, Seborrheic keratosis, Sebaceous hyperplasia, Keratosis, Dermatology, Seborrhoeic dermatitis

Pulse Biosciences will now expand its controlled commercial launch of the CellFX System to select medical practices in Canada for the treatment of general dermatologic conditions, including sebaceous hyperplasia, seborrheic keratosis and cutaneous non-genital warts.

Key Points: 
  • Pulse Biosciences will now expand its controlled commercial launch of the CellFX System to select medical practices in Canada for the treatment of general dermatologic conditions, including sebaceous hyperplasia, seborrheic keratosis and cutaneous non-genital warts.
  • I am thrilled to be the first dermatologist in Canada to provide the clinical advantages of the CellFX System using NPS technology.
  • Health Canada approval marks an important corporate milestone in our regulatory strategy and enables the planned expansion of our CellFX System Controlled Launch program in Canada this quarter.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.